Laboratory pipette with drop of liquid over glass test tubes in a science research lab

18 May 2022 - AGM statement

The company has confirmed that trading in the first four months of 2022 has been satisfactory with customer demand remaining strong, whilst the integration of ScarAway and the rights to Kelo-cote in the US (acquired in March 2022) is progressing well.  The group has emphasised once again that the performance for 2022 will be weighted towards the second half of the year with increased sales from Amberen and Nizoral expected whilst the first half has seen some supply chain issues due to lockdowns in China.  We therefore maintain our forecast of pre-tax profits . . .

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.

Already a member, log in HERE.